Sugi Predict

Sugi Predict / Compounds / SCHEMBL4352140

SCHEMBL4352140

SCHEMBL4352140

O=C(O)CCCC1CCCC1

nearest known ligand 0.56

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ KDM5A P29375 4/20 0.56
▸ PHF8 Q9UPP1 4/20 0.56
▸ KDM2A Q9Y2K7 4/20 0.56
▸ KDM4C Q9H3R0 3/20 0.56
▸ KDM4A O75164 1/20 0.54
▸ HPGD P15428 1/20 0.48
▸ LMNA P02545 3/20 0.47
▸ KDM7A Q6ZMT4 1/20 0.46
▸ SLC22A6 Q4U2R8 1/20 0.46
▸ ALDH1A1 P00352 1/20 0.45
▸ ITGB3 P05106 2/20 0.45
▸ ITGA2B P08514 2/20 0.45
▸ MAPT P10636 1/20 0.44
▸ CYP1A2 P05177 1/20 0.44
▸ TSHR P16473 1/20 0.43
▸ NFKB1 P19838 1/20 0.43
▸ PMP22 Q01453 1/20 0.43
▸ EPHX2 P34913 1/20 0.43
▸ ALOX5 P09917 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9133016 0.98 KDM5A (0.57) KDM5APHF8KDM2AKDM4CKDM4A
SCHEMBL7677761 0.98 KDM5A (0.57) KDM5APHF8KDM2AKDM4CKDM4A
SCHEMBL225946 0.98 KDM5A (0.57) KDM5APHF8KDM2AKDM4CKDM4A
Hydrochloric Acid SCHEMBL16054798 0.98 KDM5A (0.54) KDM5APHF8KDM2AKDM4CKDM4A
SCHEMBL6434889 0.96 KDM5A (0.56) KDM5APHF8KDM2AKDM4CKDM4A
SCHEMBL3888070 0.96 KDM5A (0.56) KDM5APHF8KDM2AKDM4CKDM4A
SCHEMBL440834 0.96 KDM5A (0.56) KDM5APHF8KDM2AKDM4CKDM4A
SCHEMBL7290094 0.96 KDM5A (0.56) KDM5APHF8KDM2AKDM4CKDM4A
SCHEMBL2525739 0.96 KDM5A (0.56) KDM5APHF8KDM2AKDM4CKDM4A
SCHEMBL3886708 0.96 KDM5A (0.56) KDM5APHF8KDM2AKDM4CKDM4A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-4216713-B2 — — 2009-01-28 — — JP claimed
WO-2006105842-A1 SYNERGISTS FOR BOOSTING THE ACTION OF REPELLENTS MERCK PATENT GMBH (DE) 2006-10-12 — — WO claimed
EP-1404324-A4 PRODRUGS OF GABA ANALOGS, COMPOSITIONS AND USES THEREOF XENOPORT INC (US) 2004-12-22 — — EP claimed
JP-2004536873-A — — 2004-12-09 — — JP claimed
EP-1404324-A2 PRODRUGS OF GABA ANALOGS, COMPOSITIONS AND USES THEREOF Xenoport, Inc. (US) 2004-04-07 — — EP claimed
WO-2002100347-A2 PRODRUGS OF GABA ANALOGS, COMPOSITIONS AND USES THEREOF XENOPORT, INC. (US) 2002-12-19 — — WO claimed
EP-3204382-B1 HETEROARYL COMPOUNDS AS BTK INHIBITORS AND USES THEREOF MERCK PATENT GMBH (DE) 2021-12-01 — — EP disclosed
US-20190233417-A1 HETEROARYL COMPOUNDS AS BTK INHIBITORS AND USES THEREOF MERCK PATENT GMBH (DE) 2019-08-01 — — US disclosed
US-10253023-B2 Heteroaryl compounds as BTK inhibitors and uses thereof MERCK PATENT GMBH (DE) 2019-04-09 — — US disclosed
EP-3204382-A1 HETEROARYL COMPOUNDS AS BTK INHIBITORS AND USES THEREOF Merck Patent GmbH (DE) 2017-08-16 — — EP disclosed
CN-107001362-A Heteroaryl compound as BTK inhibitor and application thereof 默克专利有限公司 2017-08-01 — — CN disclosed
US-20170135994-A9 NAMPT INHIBITORS ABBVIE INC. (US) 2017-05-18 — — US disclosed
US-20160184281-A1 NAMPT INHIBITORS ABBVIE INC. (US) 2016-06-30 — — US disclosed
WO-2013170112-A1 NAMPT INHIBITORS ABBVIE INC. (US) 2013-11-14 — — WO disclosed
US-20130303508-A1 NAMPT INHIBITORS ABBVIE INC. (US) 2013-11-14 — — US disclosed
US-20130303511-A1 NAMPT INHIBITORS ABBVIE INC. (US) 2013-11-14 — — US disclosed
WO-2006105842-A1 SYNERGISTS FOR BOOSTING THE ACTION OF REPELLENTS MERCK PATENT GMBH (DE) 2006-10-12 — — WO disclosed
EP-0319316-A2 Griseolic acid monoesters, their preparation and use SANKYO COMPANY LIMITED (JP) 1989-06-07 — — EP disclosed
US-4396620-A BACTERICIDES ELI LILLY AND COMPANY (US) 1983-08-02 — — US disclosed
US-4382931-A 3'-Substituted quinolinium cephalosporins ELI LILLY AND COMPANY (US) 1983-05-10 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10253023-B2 Heteroaryl compounds as BTK inhibitors and uses thereof BTK, SYK, LYN KDM5A 1797/4885PHF8 993/4885KDM2A 1352/4885
US-20190233417-A1 HETEROARYL COMPOUNDS AS BTK INHIBITORS AND USES THEREOF BTK, SYK, LYN KDM5A 2410/4885PHF8 977/4885KDM2A 1491/4885
US-20130303508-A1 NAMPT INHIBITORS NAMPT, NNMT, NAPRT KDM5A 3903/4885PHF8 3032/4885KDM2A 3043/4885
US-20130303511-A1 NAMPT INHIBITORS NAMPT, NNMT, NAPRT KDM5A 3903/4885PHF8 3032/4885KDM2A 3043/4885
US-20160184281-A1 NAMPT INHIBITORS NAMPT, NNMT, NAPRT KDM5A 3903/4885PHF8 3032/4885KDM2A 3043/4885
US-20170135994-A9 NAMPT INHIBITORS NAMPT, NNMT, NAPRT KDM5A 3903/4885PHF8 3032/4885KDM2A 3043/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.